The liver exposure to gut-derived microbial products, such as LPS, and the resulting activation of TLR-4 signalling in HSCs is now emerging as one of the key event in NAFLD-related fibrosis and inflammation [29, 30]. This evidence concerns the gene TLR4 and metabolic dysfunction-associated steatotic liver disease.